Therapeutic and palliative options for diffuse neuroendocrine metastatic disease

Journal of Gastrointestinal Surgery

Volumn 10, Issue 3, 2006, Pages 337-340

  Holen, Kyle ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33644556879     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gassur.2005.08.026     Document Type: Editorial

References (30)

1. R. Brentjens, and L. Saltz Islet cell tumors of the pancreas: the medical oncologist's perspective Surg Clin North Am 81 2001 527 542
2. R. Delcore, and S.R. Friesen Gastrointestinal neuroendocrine tumors J Am Coll Surg 178 1994 187 211
3. J.R. Pisegna, and M.P. Sawicki Neuroendocrine pancreas C.M. Haskell Cancer Treatment 2001 W.B. Saunders Philadelphia 1065 1081
4. L. Saltz, N. Kemeny, G. Schwartz, and D. Kelsen A phase II trial of alpha-interferon and 5fluorouracil in patients with advanced carcionid and islet cell tumors Cancer 73 1994 958 961
5. K. Oberg Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment Ann Oncol 10 Suppl 2 1991 S3 S8
6. D. Furlan, R. Cerutti, and S. Uccella Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract Clin Cancer Res 10 2004 947 957
7. K. Oberg Chemotherapy and biotherapy in the treatment of neuroendocrine tumors Ann Oncol 12 Suppl 2 2001 S111 S114
8. S. Faiss, U.F. Pape, and M. Bohmig Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - The International Lanreotide and Interferon Alfa Study Group J Clin Oncol 21 2003 2689 2696
9. C.G. Moertel, M. Lefkopoulo, S. Lipsitz, R. Hahn, and D. Klaassen Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 1992 519 523
10. P.N. Cheng, and L.B. Saltz Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma Cancer 73 1999 944 948
11. D. Sarker, M. Williams, and R. Begent 5-fluorouracil, cisplatin and streptozocin (FCiSt) is an effective new regimen for advanced pancreatic neuroendocrine tumours Proc Am Soc Clin Oncol 2004 abstract 100
12. C.G. Moertel, and J.A. Hanley Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome Cancer Clin Trials 2 1979 327 334
13. P.F. Engstrom, P.T. Lavin, C.G. Moertel, E. Folsch, and H.O. Douglass Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor J Clin Oncol 2 1984 1255 1259
14. R.M. Bukowski, K.G. Johnson, and R.F. Peterson A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors: a Southwest Oncology Group study Cancer 60 1987 2891 2895
15. M.H. Shah, D. Young, and H.L. Kindler Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors Clin Cancer Res 10 18 Pt 1 2004 6111 6118
16. M.H. Kulke, H. Kim, and J.W. Clark A phase II trial of gemcitabine for metastatic neuroendocrine tumors Cancer 101 2004 934 939
17. A. Kaubisch, R. Kaleya, H. Haynes, A. Rozenblit, and S. Wadler Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors Cancer Chemother Pharmacol 53 2004 337 340
18. S. Ansell, H. Pitot, P. Burch, L. Kvols, M. Mahoney, and J. Rubin A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 2001 1543 1548
19. M.H. Kulke, H. Kim, and K. Stuart A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Investi 22 2004 353 359
20. Carr K, Yao JC, Rashid A, et al. A phase II trial of imatinib in patients with advanced carcinoid tumor. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(Suppl 14):4124.
21. L.B. Anthony, T. Carlisle, and R. Pommier An open-label phase IIA trial evaluating the safety and efficacy of EPO906 as therapy in patients with metastatic carcinoid and other neuroendocrine tumors Proc Am Soc Clin Oncol 22 2003 352
22. J. Baker, I. Schnirer, and J.C. Yao Phase II trial of irinotecan in patients with advanced carcinoid tumor Proc Am Soc Clin Oncol 2002 abstract 662.
23. H.C. Pitot IV, J. Rubin, and C.G. Moertel Phase II study of high- and low-dose 7-hydroxycoumarin (7-HC) in patients with metastatic carcinoid Proc Am Soc Clin Oncol 1995 abstract 560
24. Y. Xu, C. Ellison, and E. Martin A phase II study of thalidomide in metastatic neuroendocrine tumors Proc Am Soc Clin Oncol 2002 abstract 1931
25. L.B. Anthony, E. Matthews, and M. Cronin Continuous low-dose capecitabine produces significant biochemical responses in patients with progressive gastroenteropancreatic (GEP) neoplasms Proc Am Soc Clin Oncol 2001 abstract 2167
26. S.M. Ansell, H.C. Pitot, and P.A. Burch Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematological toxicity Proc Am Soc Clin Oncol 2001 abstract 2302
27. M. Kulke, E. Bergsland, and D.P. Ryan A phase II, open-label, safety, pharmacokinetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors Proc Am Soc Clin Oncol 22 2003 239
28. J.J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells Mol Cancer Ther 4 2005 910 917
29. R.S. Sippel, J.E. Carpenter, and M. Kunnimalaiyaan Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells Am J Physiol Gastrointest Liver Physiol 285 2003 G245 G254
30. R.S. Sippel, and H. Chen Activation of the ras/raf-1 signal tranduction pathway in carcinoid tumor cells results in morphologic transdifferentiation Surgery 132 2002 1035 1039